BioSyent Announces Health Canada Approval of New Women’s Health Product

Posted on May 15, 2019


BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Tibella® (tibolone), indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause. 

Tibella® is a prescription hormone replacement therapy (“HRT”) consisting of tibolone. Tibella® is different from other HRTs, as it does not contain actual hormones. Instead, the body breaks down tibolone to make three substances that act like estrogen, progesterone, and testosterone.  These substances act on different tissues in the body to help treat symptoms of menopause.  Tibella® substitutes for the loss of estrogen production in postmenopausal women and alleviates menopausal symptoms. 

Read More